Displaying 1 to 20 of 28 investments
Country Date Notes
Altheos Inc
A drug development company focused on next generation intraocular pressure (IOP) lowering agents for glaucoma and ocular hypertension.
United States 1 Feb 2012 Series A
Active
Amira Pharmaceuticals Inc
A small molecule pharmaceutical company focused on the discovery and early development of compounds.
United States N/A
Amira Pharmaceuticals Inc
A small molecule pharmaceutical company focused on the discovery and early development of compounds.
United States N/A
Asante Solutions Inc
Developing a disposable drug delivery system which initially will be used for insulin delivery for Type I diabetics.
United States N/A
Cabrellis Pharmaceuticals Corp
Development of important therapies for the treatment of cancer
United States 7 Aug 2006 Series A
Conforma Therapeutics Corp
Novel drugs company for the selective treatment of cancer.
United States N/A
Delenex Therapeutics AG
Switzerland 1 May 2011 Series A
Gloucester Pharmaceuticals Inc
United States N/A
High Throughput Genomics Inc
United States 1 Feb 2011 Series D
Active
Imagen Biotech Inc
United States N/A
Inogen Inc
Developer and manufacturer of homecare products and services for oxygen therapy patients.
United States N/A
Light Sciences Oncology Inc
Drug-device cancer therapy
United States 1 Dec 2005 Series A
Logical Therapeutics Inc
An early stage biotechnology company
United States N/A
Lux Biosciences Inc
Clinical stage biotechnology company specializing in the development and commercialization of innovative medications for serious ophthalmic diseases.
United States N/A
MediQuest Therapeutics Inc
A specialty pharmaceutical company developing topical therapies to treat patients suffering from inflammatory and infectious diseases.
United States N/A
NeuroTherapeutics Pharma Inc
United States N/A
Ophthotech Corp
Clinical-stage biotechnology company, engages in developing and commercializing therapies for wet and dry age-related macular degeneration.
United States N/A
Orphazyme ApS
Orphazyme develops innovative new therapies for the treatment of a family of serious genetic disordes called lysosomal storage diseases.
Denmark 14 Feb 2011 Seed
Initial investment. Round participant. Active
Orphazyme ApS
Orphazyme develops innovative new therapies for the treatment of a family of serious genetic disordes called lysosomal storage diseases.
Denmark 1 Sep 2011 Series A
Follow-on investment. Round participant. Active
Panmira Pharmaceuticals LLC
Pharmaceutical company for inflammatory diseases.
United States N/A